Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this two-part study, a 7-day CC-486 dosing schedule showed clinical activity, was generally well tolerated, and reduced DNA methylation. Extending d...

Descripción completa

Detalles Bibliográficos
Autores principales: Laille, Eric, Shi, Tao, Garcia-Manero, Guillermo, Cogle, Christopher R., Gore, Steven D., Hetzer, Joel, Kumar, Keshava, Skikne, Barry, MacBeth, Kyle J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546409/
https://www.ncbi.nlm.nih.gov/pubmed/26296092
http://dx.doi.org/10.1371/journal.pone.0135520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546409/
https://www.ncbi.nlm.nih.gov/pubmed/26296092
http://dx.doi.org/10.1371/journal.pone.0135520

Ejemplares similares